PATENT CLAIM ANALYSIS

Application Number: 16063515
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["424", "133100"]

Abstract:
The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.

Claim (Index 2):
The anti-Myl9 antibody or Myl9 binding fragment thereof according to  claim 1 , wherein said antibody is a humanized or chimeric antibody.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 94.0
- Lexical Diversity: 1.7
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14893122', '15667644', '15753611', '13143253', '14041479']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7688264779711691
- 35 USC 102 Novelty (BERT): 0.5750261736828451
- Combined Prediction Score: 0.7494464475423368
- Mean Citation Score: 424.29052800000005
- Max Citation Score: 484.71527
- Similarity Product: 361.43854098620767

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test